Table 2.
Antiproliferative activities of compound FNA against human cancer cells (IC50, μM)a.
| Cell line | FNA (μM) | SAHA (μM) |
|---|---|---|
| HepG2 | 1.30 ± 0.25 | 17.25 ± 0.46 |
| U937 | 0.55 ± 0.03 | 0.86 ± 0.03 |
| H460 | 4.73 ± 0.05 | 7.63 ± 0.03 |
| SW480 | >100 | 2.91 ± 0.04 |
| OS-RC-2 | >100 | >100 |
| H322 | 6.36 ± 0.07 | 2.54 ± 0.06 |
| SK-NEP-1 | 8.32 ± 0.18 | 3.68 ± 0.02 |
| FTC-133 | 9.09 ± 0.13 | 24.30 ± 0.10 |
| SW579 | 52.40 ± 0.13 | 24.30 ± 0.07 |
| MDA-MB-231 | 35.29 ± 0.03 | 5.82 ± 0.08 |
| A549 | 33.74 ± 0.04 | 4.92 ± 0.04 |
| A2780 | 4.30 ± 0.12 | 2.71 ± 0.09 |
| Hela | 1.41 ± 0.04 | 1.89 ± 0.05 |
| K562 | 1.31 ± 0.05 | 2.52 ± 0.05 |
| U266 | 0.63 ± 0.32 | 0.22 ± 0.03 |
a
Assays were performed in replicate (n ≥ 2).